Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’

FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.